Introduction
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grade of severity, and it has been shown to yield a positive predictive value for the diagnosis of Crohn's disease of only 50 % -69 % [6] . The recently introduced quantitative scoring systems such as the Lewis score [7] and the capsule endoscopy Crohn's disease activity index (CECDAI or Niv Score) [8] have overcome some of these limitations. The CECDAI has been validated recently in a multicenter prospective study [9] , whereas the Lewis score has not yet undergone such validation. Nevertheless, the Lewis score, a cumulative scoring system based on the characteristics and distribution of villous edema, ulceration, and stenosis, has been converted into a user-friendly software application, which calculates the score automatically. With this application, the small bowel is automatically divided into equal thirds (tertiles) based on the transit time of the capsule. For each tertile, a numeric subscore (based on the extent and distribution of edema, and the number, size, and distribution of ulcers) is calculated. Using the software application to calculate the Lewis score, the small bowel was automatically divided into equal thirds (tertiles) based on the transit time of the capsule. In those cases where the capsule did not reach the cecum, small-bowel tertiles were determined based on the last small-bowel image available and the relative position of the capsule to the ileocecal valve, as estimated using topographic landmarks with the localization track of the RAPID software. For each tertile, a numeric subscore (based on the extent and distribution of edema, and the number, size, and distribution of ulcers) was calculated. The final score was calculated as the cumulative sum of the worst-affected tertile considering villous edema and ulcers, plus the score for stenosis (single/ multiple, ulcerated/not ulcerated, traversed/not traversed by the capsule); the stenosis score was determined for the whole examination only and not for each tertile (• " Table 1) . Small-bowel inflammatory activity was classified into three grades: 1) normal or clinically insignificant mucosal inflammatory change (score < 135); 2) mild disease (score ≥ 135 -< 790); and 3) moderate-tosevere disease (score ≥ 790). Normal -0 S h o r t s e g m e n t -8 S i n g l e -1 
Single -14 Nonulcerated -2 N o t t r a v e r s e d -10
Multiple -20
Lewis score: Score of the worst-affected tertile [(villous parameter × extent × descriptor) + (ulcer number × extent × size)] + stenosis score (number × ulcerated × traversed). 1 Longitudinal extent: short segment: < 10 % of the tertile; long segment: 11 % -50 % of the tertile; whole tertile: > 50 % of the tertile. 2 Ulcer number: single: 1; few: 2 -7; multiple: ≥ 8. 3 Ulcer descriptor (size): proportion of the capsule picture filled by the largest ulcer.
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Statistical analysis
The mean Lewis score from each investigator was compared with that from the central reader using the paired samples t test. The interobserver correlation, comparing the scoring results between the investigators and the central reader, was measured using the Pearson correlation coefficient, for both the individual quantitative scores for each tertile as well as the global small-bowel score.
Pearson correlation coefficients were considered to be low if r ≤ 0.35, moderate if 0.36 < r < 0.67, high if 0.68 < r < 0.89, and very high if r > 0.90. Interobserver agreements between each investigator and the central reader were determined, both for each tertile and for the whole examination, using the intraclass correlation coefficient (ICC), and Bland -Altman plots were drawn for the global score. ICC was interpreted as follows: 0 -0.2 poor agreement; 0.3 -0.4 fair agreement; 0. Table 2 . Overall, small-bowel inflammatory activity was classified as normal (score < 135) in 2.9 % vs. 2.9 %, mild (score ≥ 135 -< 790) in 51.4 % vs. 55.7 %, and moderate to severe (score ≥ 790) in 45.8 % vs. 41.4 % of patients, respectively (κ = 0.7; P < 0.001). The cecum was reached in 84.3 % and 87.1 % of examinations according to investigators and the central reader, respectively (κ = 0.884). Incomplete small-bowel examination was caused by delayed passage of the capsule at a previously unknown small-bowel stenosis in a minority of these patients (n = 4). These capsules were spontaneously excreted, without the need for further intervention. In the remaining examinations, the procedure was incomplete because of battery exhaustion before the capsule entered the cecum, as a result of delayed gastric passage or slow smallbowel transit. Overall, the diagnosis of small-bowel stenosis was established in 14.3 % (n = 10) and 18.6 % (n = 13) of patients, as evaluated by the investigators and the central reader, respectively (κ = 0.855). There was a high or very high correlation for scoring results with almost perfect interobserver agreement. Interestingly, the analysis of Bland -Altman plots indicates that interobserver agreement may be lower for the highest scores, considering absolute numeric values, although it does not seem to influence the assessment of global disease severity according to the classification of the Lewis score, which stratifies small-bowel inflammatory activity into three grades (< 135, normal or clinically insignificant mucosal inflammatory change; ≥ 135 -< 790, mild disease; and ≥ 790, moderate-to-severe disease). Indeed, overall, the differences between investigators, according to this classification, did not affect the global assessment of disease severity, which is clinically meaningful: to date, no study has evaluated whether there are different clinical or prognostic implications associated with scores of different magnitude above the cutoff of 790, and therefore there is uncertainty over whether these differences may be clinically relevant. The availability of an objective scoring system to assess inflammatory activity and disease extent enables the use of a common language and methodology for the interpretation and description of lesions consistent with Crohn's disease, and it may contribute to the establishment of cutoff levels indicative of the grade of severity with an adequate interobserver agreement. The adoption of reproducible scoring systems has been encouraged by recently published European Crohn's and Colitis Organisation guidelines [1] . The Lewis score [7, 10] is a cumulative scoring system based on the presence and distribution of villous edema, ulceration, and stenosis, which were the endoscopic findings with the highest interobserver agreement according to the original authors of the score (κ = 0.48, κ = 0.66, and κ = 0.58, respectively). Due to low interobserver agreement and/or perceived lack of clinical significance, other mucosal findings such as minor mucosal breaks, erythema, villous atrophy, or nodularity [10] were not included for the calculation of the score. The easy-to-use software application for the automatic calculation of the Lewis score is a clear advantage of the instrument compared with CECDAI, which currently has no software tool for its automatic calculation. Moreover, no threshold levels of inflammatory activity have been defined for CECDAI, although it has been suggested that CECDAI levels of 3.8 and 5.8 may correspond to the Lewis score thresholds of 135 and 790, respectively [11] . A wide range of different clinical scenarios require the objective assessment of small-bowel inflammatory activity in clinical practice. In patients with suspected Crohn's disease after nondiagnostic ileocolonoscopy, it is possible to confidently exclude the diagnosis if no significant small-bowel mucosal changes are identified by the capsule, because the capsule has high sensitivity even for subtle mucosal changes [6, 12] . Conversely, SBCE may be a key diagnostic tool in this setting if it reveals small-bowel lesions consistent with Crohn's disease in a proper clinical context. In this study, the gold standard for the diagnosis of Crohn's dis- ease did not rely solely on SBCE findings, but resulted from a combination of all available follow-up data, as described in the Methods section. Indeed, the diagnosis of Crohn's disease is confirmed histologically in only a minority of patients in routine clinical practice [13] , either due to the inaccessibility of lesions or because biopsies are also often unspecific. Thus, usually the diagnosis is based on a conjunction of clinical, biochemical, endoscopic, and imaging elements. In our center, we do not routinely perform flexible enteroscopy to obtain biopsies of small-bowel lesions that are consistent with Crohn's disease as detected by SBCE if the patient has a high pre-test probability of Crohn's disease. In a recent study from our center in patients with suspected Crohn's disease, the diagnosis was confirmed during follow-up in 82.6 % of those with significant inflammatory activity on SBCE (Lewis score ≥ 135), but in only 12.1 % of those with a score lower than 135 [14] . However, although the Lewis score can be used to quantitatively describe the type, distribution, and severity of mucosal lesions, endoscopic findings are nonspecific [4] , and scoring systems grade inflammatory activity independently of its etiology. Indeed, lesions resembling Crohn's disease on SBCE are indistinguishable from NSAID-induced enteropathy or other causes of small-bowel mucosal damage such as infections, Behçet disease, ischemia, or vasculitis [1] . To date, no study has addressed whether the interobserver variability could be influenced by the type of indication for SBCE, namely whether the inflammatory activity would be graded differently in patients with suspected Crohn's disease or an alternative diagnosis compared with those with a previously known established diagnosis of Crohn's disease. Although this seems unlikely when a standard, objective, and validated methodology for the assessment of inflammatory activity is followed, this is an interesting topic of investigation that could merit further investigation. The role of SBCE in patients with previously established Crohn's disease is currently evolving. It may be used to evaluate disease extent and activity in the small bowel, as proximal and/or extended inflammatory activity has been shown to be associated with poor prognosis and adverse outcomes [15, 16] , and it may have an impact on therapeutic management towards an earlier introduction of immunomodulators and/or biologic therapy [17 -19] . In a recently published retrospective study from our center, treatment with thiopurines and/or biologics was started more often in patients with proximal small-bowel lesions [13 /33 (39 %) vs. 1 /17 (6 %); P = 0.011, relative risk 6.5], particularly when severe as determined by the Lewis score (6 %, 36 %, and 45 % of patients with nonsignificant, mild, and moderate-to-severe inflammation, respectively) [18] . SBCE may also be considered in the postoperative setting [20, 21] , or to investigate patients with atypical symptoms, unexplained anemia, or obscure gastrointestinal bleeding [1] . SBCE has also been evaluated as a noninvasive diagnostic tool for the assessment of mucosal healing after therapy, an important end point of treatment efficacy, which has been associated with sustained clinical remission and improved outcomes [1, 22, 23] . For all these indications, the objective quantification of small-bowel inflammatory activity by using a validated scoring methodology seems pivotal. In this study, a strong correlation was demonstrated between the investigators and the central reader, both for scores obtained for each tertile as well as for the global Lewis score. Although the study was retrospective, it was based on prospectively collected database. A strong interobserver agreement was demonstrated for the Lewis score, validating this score for the reporting of small-bowel inflammation in a practical clinical setting. Previous studies have evaluated the correlation of endoscopic scoring systems with clinical objective measures, such as the Crohn's disease activity index or the inflammatory bowel disease questionnaire. Although this could be a topic for future investigations, several previous trials have failed to demonstrate an association between endoscopic scores and clinical scores in Crohn's disease [9, 24, 25] . This may be due to the fact that clinical activity is objectively difficult to assess, and also because symptoms such as abdominal pain or diarrhea that may resemble Crohn's disease flare-ups may be multifactorial and unrelated to the existence of prominent gastrointestinal inflammatory lesions [9, 24, 25] . To summarize, the Lewis score has been shown to be a practical and reproducible instrument that might be used in the diagnosis, staging, follow-up, and therapeutic assessment of patients with isolated small-bowel Crohn's disease.
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